Skip to main content
TipRanks
Go Ultimate75% OFF

DBV Technologies SA - American (DBVT) AI Stock Analysis

462 Followers
DBVT

DBV Technologies SA - American

(NASDAQ:DBVT)

Select Model
Rating:49Neutral
Price Target:$11.00â–²(13.64% Upside)
Action:reiterated
Date:10/30/26

Overall score reflects weak financial performance driven by ongoing losses and significant cash burn, with moderate offset from a low-debt balance sheet. Earnings-call progress (BLA submission and runway into Q3 2027) supports the outlook but is constrained by regulatory/manufacturing execution risks. Technicals remain broadly bearish with the stock below key longer-term moving averages.

Positive Factors
Regulatory ProgressThe completed BLA submission is a material step toward converting DBV from a development-stage biotech into a commercial company. It advances the lead program into formal regulatory review, creates a defined approval pathway, and supports preparations for potential product commercialization.
Negative Factors
Persistent Operating LossesDBV has not yet established recurring commercial revenue to support its operating cost base, and losses have widened substantially. Until a product is approved and generates sales, profitability depends on continued external funding and successful execution of the development pipeline.

DBV Technologies SA - American (DBVT) vs. SPDR S&P 500 ETF (SPY)

-50%-25%0%25%50%75%100%DBVT-27.65%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$231.56M
Dividend Yield
―
Average Volume (3M)
350.43K
Price to Earnings (P/E)
-3.2
Beta (1Y)
0.17
Revenue Growth
―
EPS Growth
42.37%
Country
US
Employees
125
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical tr...

DBV Technologies SA - American Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|% Change Since:-9.11%|Next Earnings Date:Mar 11, 2027
Earnings Call SentimentPositive

The call was predominantly positive, centered on the completed 4-through-7 BLA submission, cash funding into the third quarter of 2027, progress toward commercial readiness, FDA engagement and continued advancement of the toddler program. However, the company still faces significant execution and regulatory dependencies, including Fareva's unresolved Warning Letter remediation, an unscheduled FDA reinspection, pending Priority Review decisions, uncertainty around the toddler BLA process and higher operating expenses.

Positive Updates

BLA Submitted for Children Aged 4 to 7
DBV Technologies submitted its Biologics License Application for VIASKIN Peanut Patch in children aged 4-through-7 years, which management described as the highlight of the third quarter and an important step toward becoming a commercial company.

Negative Updates

Fareva Warning Letter Creates Site-Wide Remediation Challenge
Fareva Amboise received an FDA Warning Letter following a September 2025 inspection of veterinary-product manufacturing. The observations focused on quality-management operations and systems and have site-wide implications at the Amboise facility, requiring ongoing remediation relevant to VIASKIN Peanut Patch manufacturing.

Company Guidance

DBV estimates that its existing cash will fund operations into the third quarter of 2027, expects to submit a toddler BLA in 2027, and included a PAI readiness target date after Fareva expects to have completed remediation, with February 1 shared with the FDA as the date it would be ready for an inspection; the company said it is planning for the best case scenario, which is a tight timeline, with no extra buffer time, and remains comfortable that all that can be managed within the clock of Priority Review. DBV said setting up a new facility takes about 3 years, is looking at a sales force of 50 to 70 people to target 4,500 allergists in the U.S., and said you launch a blockbuster on 18 months of preparation; it will not be providing guidance on first year sales potential.

DBV Technologies SA - American Financial Statement Overview

Summary

Financial profile is weak due to zero/minimal revenue, widening operating losses, and heavy cash burn (TTM free cash flow around -$267M). This is partially offset by a comparatively solid balance sheet with low leverage and a still-meaningful equity cushion, but ongoing losses increase future funding risk.

Income Statement

18Very Negative

Balance Sheet

63Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue00015.73M4.84M5.71M
Gross Profit00-6.81M15.73M4.84M-4.68M
EBITDA-198.17M-143.86M-110.99M-63.27M-83.47M-91.16M
Net Income-207.33M-146.95M-113.72M-72.73M-96.27M-97.81M
Balance Sheet
Total Assets215.40M233.72M65.66M182.99M246.52M146.32M
Cash, Cash Equivalents and Short-Term Investments165.70M194.17M32.46M141.37M209.19M77.30M
Total Debt20.70M21.68M7.80M6.55M10.03M10.66M
Total Liabilities66.70M64.95M38.27M42.80M52.06M47.29M
Stockholders Equity148.60M168.77M27.39M140.19M194.45M99.03M
Cash Flow
Free Cash Flow-267.70M-121.71M-106.81M-80.33M-56.45M-109.16M
Operating Cash Flow-266.98M-121.18M-104.47M-79.65M-55.70M-108.24M
Investing Cash Flow-6.84M-1.37M-757.00K-808.00K-100.00K-433.00K
Financing Cash Flow384.97M276.18M587.00K6.77M194.10M274.00K

DBV Technologies SA - American Technical Analysis

Technical Analysis SentimentNegative
Last Price9.68

Price Trends

50DMA10.63Negative
100DMA12.56Negative
200DMA16.19Negative

Market Momentum

MACD-0.00Negative
RSI42.69Neutral
STOCH19.39Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Negative. The current price of 9.68 is below the 20-day moving average (MA) of 10.31, below the 50-day MA of 10.63, and below the 200-day MA of 16.19, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 42.69 is Neutral, neither overbought nor oversold. The STOCH value of 19.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DBVT.

DBV Technologies SA - American Risk Analysis

DBV Technologies SA - American disclosed 79 risk factors in its most recent earnings report. DBV Technologies SA - American reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.There is uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt about our ability to continue as a going concern.Q3, 2026

DBV Technologies SA - American Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DBVT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FDMTFDMT51Neutral$589.73M-3.75-47.06%―79952.50%29.07%
LRMRLRMR51Neutral$337.45M-1.93-134.23%――-27.00%
DBVTDBVT49Neutral$603.43M-3.20-121.83%――42.37%
KRROKRRO48Neutral$170.75M-1.37-117.05%―-82.47%3.73%
LXEOLXEO43Neutral$236.36M-2.36-45.29%――53.48%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%DBVTLRMRKRROFDMTLXEODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DBVT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DBVTDBV Technologies S.A. - American Depositary Shares9.68-4.07-29.60%
LRMRLarimar Therapeutics, Inc.3.23-0.33-9.41%
KRROKorro Bio, Inc.12.446.1698.09%
FDMT4D Molecular Therapeutics, Inc.10.46-0.38-3.51%
LXEOLexeo Therapeutics, Inc.2.95-6.11-67.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026